Polygenic Score (PGS) ID: PGS000037

Predicted Trait
Reported Trait Asthma
Mapped Trait(s) asthma (MONDO_0004979)
Released in PGS Catalog: Dec. 18, 2019
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PGS_AST
Development Method
Name Pruning and Thresholding (P+T)
Parameters p < 5×10^-8 from meta-analysis in Moffatt 2010; R2 threshold 0.60
Variants
Original Genome Build NR
Number of Variants 15
Effect Weight Type NR
PGS Source
PGS Catalog Publication (PGP) ID PGP000025
Citation (link to publication) Belsky DW et al. Lancet Respir Med (2013)
Ancestry Distribution
Source of Variant
Associations (GWAS)
Multi-ancestry (including European): 100%
  • European
  • Additional Diverse Ancestries
26,475 individuals (100%)
PGS Evaluation
European: 100%
2 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST000804
Europe PMC: 20860503
 26,475 individuals European, Other 22 cohorts
  • ALSPAC
  • ,AUGOSA
  • ,B58C
  • ,BAMSE
  • ,BHS
  • ,CAPPS
  • ,ECRHS
  • ,EGEA
  • ,G.MAS
  • ,GAIN.AST
  • ,GAS
  • ,KARELIA
  • ,KSMU
  • ,MAGICS
  • ,MRCA-UKC
  • ,PIAMA
  • ,SAGE.AST
  • ,SAPALDIA
  • ,SEVERE
  • ,SLSJ
  • ,TOMSK
  • ,UFA

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000082 PSS000055|
European Ancestry|
880 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Asthma onset, up to age 38 years HR: 1.12 [1.01, 1.26] — — sex —
PPM000083 PSS000055|
European Ancestry|
880 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Life-course-persistent asthma RR: 1.36 [1.14, 1.63] — — sex —
PPM000084 PSS000056|
European Ancestry|
187 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Asthma onset HR: 1.17 [1.01, 1.34] AUROC: 0.61 [0.53, 0.7] — sex —
PPM000085 PSS000056|
European Ancestry|
187 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Life-course-persistent asthma RR: 1.2 [1.05, 1.38] — — sex —
PPM000086 PSS000055|
European Ancestry|
880 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Atopy (skin test for common allergen 2mm > control) RR: 1.07 [1.01, 1.14] — — sex —
PPM000087 PSS000055|
European Ancestry|
880 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Airway hyper-responsiveness to methacholine or albuterol RR: 1.16 [1.03, 1.32] — — sex —
PPM000088 PSS000055|
European Ancestry|
880 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Incompletely reversible airflow obstruction (IRAO, post-bronchodilator FEV1:FVC more than 2SD below mean) RR: 1.28 [1.04, 1.57] — — sex —
PPM000089 PSS000055|
European Ancestry|
880 individuals
 PGP000025 |
Belsky DW et al. Lancet Respir Med (2013)
 Reported Trait: Admitted to hospital for asthma RR: 1.38 [1.07, 1.79] — — sex —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000055 Current asthma status was assessed at ages 9, 11, 13, 15, 18, 21, 26, 32, and 38 years from standardised interviews of study members (or their mothers if the participant was younger than 13 years) done by pulmonary specialists. Current asthma was defined as a diagnosis of asthma in addition to positive symptoms within the past 12 months, including asthma attack, recurrent wheeze (excluding study members reporting only one or two episodes lasting less than 1 h), or medical treatment for asthma. Age at asthma onset was defined as the earliest age at which wheezing symptoms or diagnosis by a physician were recorded. Median = 38.0 years
Range = [0.0, 38.0] years
[
  • 305 cases
  • , 575 controls
]
,
51.0 % Male samples
 — European — DMHDS —
PSS000056 Current asthma status was assessed at ages 9, 11, 13, 15, 18, 21, 26, 32, and 38 years from standardised interviews of study members (or their mothers if the participant was younger than 13 years) done by pulmonary specialists. Current asthma was defined as a diagnosis of asthma in addition to positive symptoms within the past 12 months, including asthma attack, recurrent wheeze (excluding study members reporting only one or two episodes lasting less than 1 h), or medical treatment for asthma. Age at asthma onset was defined as the earliest age at which wheezing symptoms or diagnosis by a physician were recorded. — 187 individuals — European — DMHDS Subset of children from DMHDS with asthma onset in childhood (before age 13 years)